-- ウェスト・レッド・レイク・ゴールド・マインズ(WRLG.V)の投資判断が、レイモンド・ジェームズによって「アウトパフォーム」から「マーケットパフォーム」に引き下げられました。 アナリストのクレイグ・スタンレー氏は、カナダの金生産・開発会社である同社の株価目標を2ドルから1ドルに引き下げました。 スタンレー氏は顧客向けレポートの中で、「同社は2026年第1四半期の金販売量と2026年の生産量見通しを発表しましたが、いずれも当社の予想を下回りました」と述べています。 「2026年第1四半期の金販売量は6,200オンスで、当社の予想である9,100オンスを下回りました。生産量、トン数、品位、冶金回収率に関する情報は提供されていません」とスタンレー氏は述べています。 「これは特に品位に関して残念な結果です。前オーナー時代のプロジェクトの実績を考えると尚更です(ただし、2025年のバルクサンプルは資源量モデルと一致していました)。」
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%